All In Biotech

NDA 020789 · Advanz Pharma

Zonegran

Zonisamide · Oral · Anti-epileptic Agent

Novel

Last checked: Nov 20, 2026Latest source record: Apr 13, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Mar 27, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

79

22 Phase 3, 1 recruiting

FAERS reports

14,830

11,239 serious, 894 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZONEGRAN · ZONISAMIDE 100MG · CAPSULE, ORAL · Prescription · TE AB
  • ZONEGRAN · ZONISAMIDE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
  • ZONEGRAN · ZONISAMIDE 25MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Zonisamide" as an intervention, any sponsor and status, largest first.

All 79 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,707
  • seizure1,667
  • off label use953
  • fatigue731
  • somnolence688
  • convulsion622
  • dizziness584
  • nausea581
  • headache569
  • fall521
  • drug interaction482
  • condition aggravated465

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004166
2005182
2006245
2007236
2008268
2009305
2010329
2011490
2012518
2013446
2014547
2015777
2016937
2017706
2018891
20191,058
2020929
20211,148
20221,093
20231,023
2024969
2025946
2026621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zonegran (Zonisamide)

2024 spending

$20.9M

Beneficiaries

675

4,783 claims

Per beneficiary

$30,939

$21.43 per unit

View as table
YearSpending
2020$21,955,276
2021$22,320,130
2022$22,805,969
2023$23,044,503
2024$20,884,145

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 224 on PubMed

Sponsor: Advanz Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.